AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03118700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Exercise
Description: Subjects will perform an interval exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time
Study NCT03118700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous exercise
Description: Subjects will perform a 30-minute continuous exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will perform a 30-minute exercise bout at a work rate associated with 75%-80% of their max HR. They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time.
Study NCT01543152 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg
Study NCT01543152 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2
Study NCT01543152 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2
Study NCT01543152 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2
Study NCT01543152 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
Study NCT02687542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02687542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751 low dose (1 mg QD)
Description: PF-06649751 low dose (1 mg QD)
Study NCT02687542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751 middle dose 1 (3 mg QD)
Description: PF-06649751 lower middle dose 1 (3 mg QD)
Study NCT02687542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751 middle dose 2 (7 mg QD)
Description: PF-06649751higher middle dose 2 (7 mg QD)
Study NCT02687542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751 high dose (15 mg QD)
Description: PF-06649751 high dose (15 mg QD)
Study NCT00612950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucagon-like peptide-1,
Description: GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
Study NCT00612950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucose dependent insulinotropic polypeptide
Description: continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
Study NCT00612950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: continuous infusion of Saline for 120 min
Study NCT04552275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Proteomics Analysis
Description: Determine a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT)
Study NCT02140697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hippophae rhamnoides L. Leaf Extract (3g/day)
Description: Hippophae rhamnoides L. Leaf extract (3g/day), parallel design
Study NCT02140697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (3g/day)
Description: Placebo (3g/day), parallel design
Study NCT01756534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL
Description: Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
Study NCT01534312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGMP protein
Description: Casein glycomacropeptide purified powder dissolved in 300 ML water once daily
Study NCT01534312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maximal oral 5ASA
Description: 4800 grams/day of Mesalazine (Asacol/Mezavant)
Study NCT02999542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Children will be randomised to receive either music via headphones or silence via headphones
Study NCT02999542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No music
Description: Children will be randomised to receive either music via headphones or silence via headphones
Study NCT04411485 — intervention group
Intervention type: OTHER
Intervention: Sexual dysfunction
Description: Sexual dysfunction will be determined with separate scales for women and men
Study NCT04660461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30mg
Description: Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
Study NCT04660461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
Study NCT02345954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Supracervical Hysterectomy and Sacropexy
Description: Laparoscopic supracervical hysterectomy and laparoscopic sacrocolpopexy
Study NCT02345954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Hysteropexy
Description: Laparoscopic hysteropexy
Study NCT04167046 — intervention group
Intervention type: PROCEDURE
Intervention: Erector spinae block
Description: Preoperative erector spinae block.
Study NCT01136135 — intervention group
Intervention type: OTHER
Intervention: CARDIAC MRI
Description: To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection and follow-up of cellular rejection in heart transplant in childhood.
Study NCT01607736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Gait Training
Description: The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
Study NCT02713542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACP
Description: Autologous Conditioned Plasma
Study NCT02713542 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three Normal Saline IA injections of 3-8 mL at 1-week intervals.
Study NCT01868256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early discharge (<72 h)
Study NCT01868256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional discharge
Study NCT04266262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Description: Supervised HIIT sessions (2x/week) will comprise cycling 10 x 60 secs at 85-95% maximum heart rate (HRmax) interspersed by 60 secs of low-intensity recovery.~Unsupervised HIIT sessions (1x/week) will involve 10 x 60 secs of walking or alternative (intensity of 7-9 on the 0-10 RPE) interspersed by 60 secs of walking or cycling at low intensity recovery (RPE 3-5).
Study NCT04266262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity resistance training (HIRT)
Description: Supervised HIRT sessions (2x/week) will comprise 2-3 sets of 6-8 repetitions progressively achieving 85% of 1RM.~Unsupervised HIRT sessions (1x/week) will involve 2-3 sets of 15-20 repetitions using a resistance exercise band when necessary.
Study NCT03739398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR))
Description: 1. LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR)) : Fractional Microneedle Radiofrequency (FMR) equipment is a device that penetrates the epidermis and irradiates the high frequency by entering the dermis. The generated radiofrequency transfers heat energy and induces thermal denaturation in the surrounding tissue. Using this principle, FMR equipment is being used as a very effective treatment for scarring, enlarged pores, hyperhidrosis as well as wrinkles. Unlike conventional treatments, FMR equipment has the advantage of a short recovery time after treatment because it minimizes damage to the epidermis because the insulated microspheres penetrate the skin and generate high frequency only at the end of the microspheres.
Study NCT03739398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASEMED laser(The Thulium laser with 1,927nm wavelength)
Description: 2. LASEMD laser(The Thulium laser with 1,927nm wavelength) The Thulium laser with 1,927nm wavelength is a device that effectively removes various skin diseases present in the epidermis while minimizing the side effects such as scarring and pigmentation because it induces thermal damage to the only skin surface compared to conventional laser equipment. In recent years, not only skin lesions on the epidermis but also pigment disease and wrinkles have been reported to have a good effect.~In this study, we investigated the effect and stability of combined treatment of Thulium laser with 1,927nm wavelength in addition to FMR equipment which has already proven to be effective in improving skin aging.
Study NCT00867789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: 10mg/kg/day (based on trimethoprim component), divided twice daily for ten days (maximum dose: 160mg (TMP component) per dose)
Study NCT00867789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: 10mg/kg/day divided twice daily for ten days. Placebo liquid will contain simple syrup, lactose powder, grape flavor, and food coloring. Placebo capsules will contain lactose powder.
Study NCT04244526 — intervention group
Intervention type: OTHER
Intervention: Talking a urine sample
Description: Just taking a urine sample
Study NCT00549939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight
Study NCT00549939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight
Study NCT01389375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemoSeal®
Description: Closure device for femoral artery access closure
Study NCT01389375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExoSeal®
Description: Closure device for femoral artery access closure
Study NCT01389375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Conventional manual compression
Study NCT02946242 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound Exam
Description: Subjects will be scheduled to attend up to up to five (5) ultrasound scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan (limited to 15 cumulative minutes of scan time per eye, per day for ophthalmic scanning) as long as they remain eligible per the study inclusion and eligibility criteria.
Study NCT02490475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
Study NCT02490475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhuMab 2C4
Description: Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
Study NCT00603460 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DCVax-L and T Cells
Description: Arm A~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* End of study visit~Arm B~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~* End of study visit
Study NCT02953353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active transcranial direct current stimulation (tDCS)
Description: Participants will receive 10 daily sessions (phase 2) and 3 times a week (phase 3) of tDCS (2mA, 30 min per session). The tDCS montage will target the left dorsolateral prefrontal cortex (DLPFC) (anode: F3 based on the 10:20 system; cathode over the right supraorbital area). For stimulation the investigators will use 5x5cm sponge pads that will be soaked in 0.9% saline during the sessions.
Study NCT02953353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Description: During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.
Study NCT02953353 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hypocaloric diet
Description: During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.
Study NCT02953353 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Description: Subjects in the control group will receive sham stimulation (placebo) (similar procedure and duration as real tDCS, but here electric current flows for 30 s only, to mimic the subjective sensations that occur with active tDCS).
Study NCT01360554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib (PF-00299804)
Description: Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing
Study NCT01360554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator (erlotinib)
Description: Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing
Study NCT01360554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo erlotinib
Description: placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.
Study NCT01360554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo PF00299804
Description: placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
Study NCT04341636 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Bitewing X ray
Description: Each patients will be exposed to 4 horizontal bitewing for posterior teeth ( standard of care ) and 4 vertical bitewing for the same area ( experimental ) . X ray will be taken using a film holder and a steel wire (3mm ) on the film holders. This steel wire will help to adjust for magnification later on. The x ray tube will be in the same distance (4mm from the x ray).~The bitewing radiographs will be taken with double-packed Ekta speed Plus films on a radiograph machine operating at 0 kilovolt peak and 8 milliampere, having 2.5 aluminium filtration and a 0.860.8 mm focal spot, according to the manufacturer's exposure recommendations, with the parallel technique to obtain an accurate x ray as much as possible . The radiographs will be processed digitally. All the x ray will be taken using the standard protection protocol .
Study NCT04341636 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bitewing X ray
Description: Each patients will be exposed to 4 horizontal bitewing for posterior teeth ( standard of care ) and 4 vertical bitewing for the same area ( experimental ) . X ray will be taken using a film holder and a steel wire (3mm ) on the film holders. This steel wire will help to adjust for magnification later on. The x ray tube will be in the same distance (4mm from the x ray).~The bitewing radiographs will be taken with double-packed Ekta speed Plus films on a radiograph machine operating at 0 kilovolt peak and 8 milliampere, having 2.5 aluminium filtration and a 0.860.8 mm focal spot, according to the manufacturer's exposure recommendations, with the parallel technique to obtain an accurate x ray as much as possible . The radiographs will be processed digitally. All the x ray will be taken using the standard protection protocol .
Study NCT04663789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reinforcement of the staple line
Description: The operator will perform reinforcement of the staple line with a continuous lock stitch.
Study NCT04663789 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: staple only
Description: The operator transect the pancreas with stapler only, without staple line reinforcement.
Study NCT04675164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Assisted Immotile Sperm Selection
Description: LAISS will be performed using diode laser system at the lowest working power with a single laser shot at the lower one third of the sperm tail. If sperm tail curling occurred, the sperm is then viable and will be utilized for ICSI after immobilization in PVP.
Study NCT04675164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypo-osmotic Swelling Test
Description: HOST will be performed by transferring immotile sperms from incubation droplet into HOST droplet, with any sperm showing tail swelling will be identified as viable and will be utilized for ICSI after immediate transfer and immobilization.
Study NCT01205230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
Study NCT01994382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerdulatinib
Description: Oral capsule
Study NCT01994382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion
Study NCT02509182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60% oxygen
Description: An inspired oxygen concentration of 60% will be administered during pulmonary lobectomy surgery.
Study NCT02509182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% oxygen
Description: An inspired oxygen concentration of 100% will be administered during pulmonary lobectomy surgery.
Study NCT01312454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-59412C injectable solution
Description: Concentration 1 and Concentration 2
Study NCT01312454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost injectable solution
Study NCT01312454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-59412C Vehicle
Description: Inactive ingredients used as placebo
Study NCT04214379 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ptosis surgery
Description: Frontalis sling surgery using pose-up and Wright's fascia-lata needle